355 related articles for article (PubMed ID: 22427353)
1. Metabolic heterogeneity in polycystic ovary syndrome is determined by obesity: plasma metabolomic approach using GC-MS.
Escobar-Morreale HF; Samino S; Insenser M; Vinaixa M; Luque-Ramírez M; Lasunción MA; Correig X
Clin Chem; 2012 Jun; 58(6):999-1009. PubMed ID: 22427353
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Novel Lipid Profiles in PCOS: Do Insulin and Androgen Oppositely Regulate Bioactive Lipid Production?
Li S; Chu Q; Ma J; Sun Y; Tao T; Huang R; Liao Y; Yue J; Zheng J; Wang L; Xue X; Zhu M; Kang X; Yin H; Liu W
J Clin Endocrinol Metab; 2017 Mar; 102(3):810-821. PubMed ID: 27886515
[TBL] [Abstract][Full Text] [Related]
3. Combining a nontargeted and targeted metabolomics approach to identify metabolic pathways significantly altered in polycystic ovary syndrome.
Chang AY; Lalia AZ; Jenkins GD; Dutta T; Carter RE; Singh RJ; Nair KS
Metabolism; 2017 Jun; 71():52-63. PubMed ID: 28521878
[TBL] [Abstract][Full Text] [Related]
4. Amino acid and fatty acid metabolomic profile during fasting and hyperinsulinemia in girls with polycystic ovarian syndrome.
Cree-Green M; Carreau AM; Rahat H; Garcia-Reyes Y; Bergman BC; Pyle L; Nadeau KJ
Am J Physiol Endocrinol Metab; 2019 May; 316(5):E707-E718. PubMed ID: 30753112
[TBL] [Abstract][Full Text] [Related]
5. Serum metabolomics profiling by proton nuclear magnetic resonance spectrometry of the response to single oral macronutrient challenges in women with polycystic ovary syndrome (PCOS) compared with male and female controls.
Escobar-Morreale HF; Martínez-García MÁ; Insenser M; Cañellas N; Correig X; Luque-Ramírez M
Biol Sex Differ; 2023 Sep; 14(1):62. PubMed ID: 37736753
[TBL] [Abstract][Full Text] [Related]
6. Alterations in plasma non-esterified fatty acid (NEFA) kinetics and relationship with insulin resistance in polycystic ovary syndrome.
Ezeh U; Arzumanyan Z; Lizneva D; Mathur R; Chen YH; Boston RC; Chen YI; Azziz R
Hum Reprod; 2019 Feb; 34(2):335-344. PubMed ID: 30576500
[TBL] [Abstract][Full Text] [Related]
7. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.
Højlund K
Dan Med J; 2014 Jul; 61(7):B4890. PubMed ID: 25123125
[TBL] [Abstract][Full Text] [Related]
8. Impaired Lipolysis, Diminished Fat Oxidation, and Metabolic Inflexibility in Obese Girls With Polycystic Ovary Syndrome.
Kim JY; Tfayli H; Michaliszyn SF; Arslanian S
J Clin Endocrinol Metab; 2018 Feb; 103(2):546-554. PubMed ID: 29220530
[TBL] [Abstract][Full Text] [Related]
9. Associations between insulin resistance, free fatty acids, and oocyte quality in polycystic ovary syndrome during in vitro fertilization.
Niu Z; Lin N; Gu R; Sun Y; Feng Y
J Clin Endocrinol Metab; 2014 Nov; 99(11):E2269-76. PubMed ID: 24694334
[TBL] [Abstract][Full Text] [Related]
10. Obese but not normal-weight women with polycystic ovary syndrome are characterized by metabolic and microvascular insulin resistance.
Ketel IJ; Stehouwer CD; Serné EH; Korsen TJ; Hompes PG; Smulders YM; de Jongh RT; Homburg R; Lambalk CB
J Clin Endocrinol Metab; 2008 Sep; 93(9):3365-72. PubMed ID: 18593766
[TBL] [Abstract][Full Text] [Related]
11. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents.
Silfen ME; Denburg MR; Manibo AM; Lobo RA; Jaffe R; Ferin M; Levine LS; Oberfield SE
J Clin Endocrinol Metab; 2003 Oct; 88(10):4682-8. PubMed ID: 14557441
[TBL] [Abstract][Full Text] [Related]
12. AKR1C3-Mediated Adipose Androgen Generation Drives Lipotoxicity in Women With Polycystic Ovary Syndrome.
O'Reilly MW; Kempegowda P; Walsh M; Taylor AE; Manolopoulos KN; Allwood JW; Semple RK; Hebenstreit D; Dunn WB; Tomlinson JW; Arlt W
J Clin Endocrinol Metab; 2017 Sep; 102(9):3327-3339. PubMed ID: 28645211
[TBL] [Abstract][Full Text] [Related]
13. Relationship among obesity, insulin resistance, and hyperinsulinemia in the polycystic ovary syndrome.
Dahan MH; Reaven G
Endocrine; 2019 Jun; 64(3):685-689. PubMed ID: 30900204
[TBL] [Abstract][Full Text] [Related]
14. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.
Jeanes YM; Reeves S
Nutr Res Rev; 2017 Jun; 30(1):97-105. PubMed ID: 28222828
[TBL] [Abstract][Full Text] [Related]
15. 11-Oxygenated C19 Steroids Are the Predominant Androgens in Polycystic Ovary Syndrome.
O'Reilly MW; Kempegowda P; Jenkinson C; Taylor AE; Quanson JL; Storbeck KH; Arlt W
J Clin Endocrinol Metab; 2017 Mar; 102(3):840-848. PubMed ID: 27901631
[TBL] [Abstract][Full Text] [Related]
16. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome.
Rajkhowa M; Neary RH; Kumpatla P; Game FL; Jones PW; Obhrai MS; Clayton RN
J Clin Endocrinol Metab; 1997 Oct; 82(10):3389-94. PubMed ID: 9329374
[TBL] [Abstract][Full Text] [Related]
17. Obesity, body composition and metabolic disturbances in polycystic ovary syndrome.
Svendsen PF; Nilas L; Nørgaard K; Jensen JE; Madsbad S
Hum Reprod; 2008 Sep; 23(9):2113-21. PubMed ID: 18556679
[TBL] [Abstract][Full Text] [Related]
18. Metabolic heterogeneity of follicular amino acids in polycystic ovary syndrome is affected by obesity and related to pregnancy outcome.
Zhang CM; Zhao Y; Li R; Yu Y; Yan LY; Li L; Liu NN; Liu P; Qiao J
BMC Pregnancy Childbirth; 2014 Jan; 14():11. PubMed ID: 24410809
[TBL] [Abstract][Full Text] [Related]
19. Adrenal androgen excess and body mass index in polycystic ovary syndrome.
Moran C; Arriaga M; Arechavaleta-Velasco F; Moran S
J Clin Endocrinol Metab; 2015 Mar; 100(3):942-50. PubMed ID: 25514100
[TBL] [Abstract][Full Text] [Related]
20. Adiposity and metabolic dysfunction in polycystic ovary syndrome.
Sam S
Horm Mol Biol Clin Investig; 2015 Feb; 21(2):107-16. PubMed ID: 25781555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
